Malaria burden in Thailand has declined since 2000 and is concentrated along borders with Myanmar and Cambodia. According to national policy, malaria should be managed exclusively in the public sector. The first-line treatment for P. falciparum has been non-fixed dose combination artesunate and mefloquine (ASMQ) and primaquine (PQ), but treatment guidelines changed in 2016 to dihydroartemisinin piperaquine (DHA PPQ). P. vivax is treated with chloroquine (CQ) and PQ. The purpose of this study was to investigate the antimalarial and diagnostic markets.